361 related articles for article (PubMed ID: 20606648)
1. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.
Chen Y; Zhu X; Zhang X; Liu B; Huang L
Mol Ther; 2010 Sep; 18(9):1650-6. PubMed ID: 20606648
[TBL] [Abstract][Full Text] [Related]
2. Small RNA combination therapy for lung cancer.
Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer.
Kanehira Y; Togami K; Ishizawa K; Sato S; Tada H; Chono S
Pharm Dev Technol; 2019 Nov; 24(9):1095-1103. PubMed ID: 31204552
[TBL] [Abstract][Full Text] [Related]
5. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases.
Kedinger V; Meulle A; Zounib O; Bonnet ME; Gossart JB; Benoit E; Messmer M; Shankaranarayanan P; Behr JP; Erbacher P; Bolcato-Bellemin AL
BMC Cancer; 2013 Jul; 13():338. PubMed ID: 23835136
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanoparticles deliver siRNA to melanoma.
Chen Y; Bathula SR; Yang Q; Huang L
J Invest Dermatol; 2010 Dec; 130(12):2790-8. PubMed ID: 20686495
[TBL] [Abstract][Full Text] [Related]
7. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis.
Yang Y; Li J; Liu F; Huang L
Mol Ther; 2012 Mar; 20(3):609-15. PubMed ID: 22186791
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer.
Yang Y; Hu Y; Wang Y; Li J; Liu F; Huang L
Mol Pharm; 2012 Aug; 9(8):2280-9. PubMed ID: 22686936
[TBL] [Abstract][Full Text] [Related]
9. Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.
Yang J; Zhao R; Feng Q; Zhuo X; Wang R
Invest New Drugs; 2021 Feb; 39(1):66-76. PubMed ID: 32794135
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition.
Bonnet ME; Gossart JB; Benoit E; Messmer M; Zounib O; Moreau V; Behr JP; Lenne-Samuel N; Kedinger V; Meulle A; Erbacher P; Bolcato-Bellemin AL
J Control Release; 2013 Sep; 170(2):183-90. PubMed ID: 23727288
[TBL] [Abstract][Full Text] [Related]
11. Enhanced endosomal escape by photothermal activation for improved small interfering RNA delivery and antitumor effect.
Yang X; Fan B; Gao W; Li L; Li T; Sun J; Peng X; Li X; Wang Z; Wang B; Zhang R; Xie J
Int J Nanomedicine; 2018; 13():4333-4344. PubMed ID: 30087564
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
13. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
14. The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA.
Xu C; Tian H; Wang P; Wang Y; Chen X
Biomater Sci; 2016 Oct; 4(11):1646-1654. PubMed ID: 27709139
[TBL] [Abstract][Full Text] [Related]
15. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.
Wang Y; Xu Z; Guo S; Zhang L; Sharma A; Robertson GP; Huang L
Mol Ther; 2013 Oct; 21(10):1919-29. PubMed ID: 23774794
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
Chen Y; Wu JJ; Huang L
Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
[TBL] [Abstract][Full Text] [Related]
17. Single-chain antibody-delivered Livin siRNA inhibits human malignant melanoma growth in vitro and in vivo.
Wang H; Yang Y; Wang W; Guan B; Xun M; Zhang H; Wang Z; Zhao Y
Tumour Biol; 2017 May; 39(5):1010428317701645. PubMed ID: 28459204
[TBL] [Abstract][Full Text] [Related]
18. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.
Wang Y; Xie Y; Kilchrist KV; Li J; Duvall CL; Oupický D
ACS Appl Mater Interfaces; 2020 Jan; 12(4):4308-4322. PubMed ID: 31939276
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles.
Liu XQ; Song WJ; Sun TM; Zhang PZ; Wang J
Mol Pharm; 2011 Feb; 8(1):250-9. PubMed ID: 21138272
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
